<DOC>
	<DOCNO>NCT02475460</DOCNO>
	<brief_summary>The purpose study evaluate less invasive implantation technique HeartMate 3 Left Ventricular Assist System ( HM 3 LVAS ) 10 patient .</brief_summary>
	<brief_title>HeartMate 3™ LIS Study</brief_title>
	<detailed_description>This study evaluate less invasive implantation technique HM 3 LVAS .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>1 . Patient legal representative sign Informed Consent Form ( ICF ) 2 . Age ≥ 18 year 3 . BSA ≥ 1.2 m2 4 . NYHA IIIB IV , ACC/AHA Stage D 5 . LVEF ≤ 25 % 6 . CI ≤ 2.2 L/min/m2 , inotropes ( Patient treat inotropes baseline , apply ) 7 . Patients must also meet one follow : On optimal medical management ( OMM ) , base current heart failure practice guideline least 45 last 60 day fail respond , OR In NYHA class IIIB IV heart failure least 14 day AND dependent intraaortic balloon pump ( IABP ) least 7 day , OR Inotrope dependent/unable wean inotropes OR Listed transplant 8 . Females child bear age must agree use adequate contraception 1 . Etiology heart failure ( HF ) due associate uncorrected thyroid disease , obstructive cardiomyopathy , pericardial disease , amyloidosis restrictive cardiomyopathy 2 . Technical obstacle pose inordinately high surgical risk , judgment Investigator 3 . Existence ongoing mechanical circulatory support ( MCS ) IABP 4 . Positive pregnancy test childbearing potential 5 . Lactating mother 6 . Presence mechanical aortic cardiac valve 7 . History organ transplant 8 . Platelet count &lt; 100,000 x 103/L ( &lt; 100,000/ml ) 9 . Psychiatric disease/disorder , irreversible cognitive dysfunction psychosocial issue likely impair compliance study protocol LVAS management 10 . History confirm , untreated AAA &gt; 5 cm diameter 11 . Presence active , uncontrolled infection 12 . Intolerance anticoagulant antiplatelet therapy peri/postoperative therapy Investigator require base upon patient ' health status 13 . Presence one follow risk factor indication severe end organ dysfunction failure : An INR ≥ 2.5 due anticoagulation therapy Total bilirubin &gt; 43 umol/L ( 2.5 mg/dl ) , shock liver , biopsy proven liver cirrhosis History severe chronic obstructive pulmonary disease ( COPD ) define FEV1/FVC &lt; 0.7 , FEV1 &lt; 50 % predict Fixed pulmonary hypertension recent PVR ≥ 8 Wood unit unresponsive pharmacologic intervention History stroke within 90 day prior enrollment , history cerebrovascular disease significant ( &gt; 80 % ) carotid artery stenosis Serum Creatinine ≥ 221umol/L ( 2.5 mg/dl ) need chronic renal replacement therapy Significant peripheral vascular disease ( PVD ) accompany rest pain extremity ulceration 14 . Aortic valve regurgitation &gt; grade 1 15 . Pre albumin &lt; 150 mg/L , Albumin &lt; 30g/L ( 3 g/dL ) 16 . Planned BiVAD support prior enrollment 17 . Patient known hypo hyper coagulable state disseminate intravascular coagulation heparin induce thrombocytopenia 18 . Planned concomitant intracardiac cardiac surgery 19 . Thrombus formation atrium leave ventricle identify echocardiogram 20 . Previous sternotomy leftsided thoracotomy 21 . Participation clinical investigation likely confound study result affect study 22 . Any condition HF could limit survival less 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HeartMate 3</keyword>
	<keyword>LVAS</keyword>
	<keyword>LVAD</keyword>
	<keyword>Heart-assist Devices</keyword>
	<keyword>Advanced</keyword>
	<keyword>Ventricular Dysfunction</keyword>
	<keyword>refractory leave ventricular</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>